EU Guide Outlines Important Considerations For Submitting Complex Trials In CTIS
Executive Summary
EU regulators have issued a new Q&A document on the key aspects that sponsors of complex trials should consider when making new submissions or moving ongoing studies to the Clinical Trials Information System.
You may also be interested in...
Not A Smooth Ride: How One Of The First Studies Navigated The EU Clinical Trial Portal
From grappling with a never-ending list of conflicting national requirements to dealing with numerous technical issues, a research project manager at Norway’s Oslo University Hospital talks about the hiccups faced by their multinational COVID-19 platform trial that was among the first studies submitted for approval under the EU Clinical Trial Regulation.
EU Offers Advice On Running Complex Clinical Trials Under CTR
New EU-wide guidance describes the factors that sponsors should consider when designing and conducting trials with complex innovative designs.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.